Haris Riaz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Haris Riaz has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
Muhammad Shahzeb Khan
Department of Internal Medicine, John H Stroger Jr, Hospital of Cook County, 969 W Ogden Ave, Chicago, IL 60612, USA
7 shared publications- Richard A. Krasuski
Duke University Medical Center, Durham, NC (R.A.K.).
5 shared publications - Faraz Khan Luni
Department of Internal Medicine, University of Toledo Medical Center, Toledo, Ohio
4 shared publications Sajjad Raza
Department of Cardiac Surgery, Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio
4 shared publicationsAbdur Rahman Khan
Department of Cardiovascular Medicine, University of Louisville, Louisville, Kentucky
3 shared publications- Irbaz Bin Riaz
Mayo Clinic, Phoenix, AZ
3 shared publications
Latest Publications
- 1 June 2020
- Published by Elsevier in The American Journal of Medicine
- Vol. 133 (6) , e218-e219
ISCHEMIA Trial: A Hope or a Hype for Patients with Stable Coronary Artery Disease?
- 1 June 2020
- Published by Elsevier in The American Journal of Medicine
- Vol. 133 (6) , e218-e219
ISCHEMIA Trial: A Hope or a Hype for Patients with Stable Coronary Artery Disease?
- 14 October 2019
- Published by Oxford University Press (OUP) in European Heart Journal - Quality of Care and Clinical Outcomes
- Vol. 6 (2) , 105-111
Residual inflammatory risk after contemporary lipid lowering therapy
Recently, there has been an increasing interest in targeting inflammation to reduce major adverse cardiovascular events (MACE) in patients with cardiovascular risk. Statins, PCSK9 inhibitors, and ezetimibe have been shown to reduce MACE owing to reduction in low-density lipoproteins cholesterol (LDL-c). Herein, we investigate whether the intensity of these agents is associated with (i) discernible reduction in inflammation measured by the levels of high-sensitivity C-reactive protein (hsCRP); (ii) reduction in MACE; (iii) if there is an association between the baseline hsCRP and MACE. Electronic databases were searched for randomized controlled trials (RCTs) that compared statins, ezetimibe, PCSK9 inhibitors with placebos/active controls and reported MACEs and hsCRP (mg/L). Studies were stratified based on baseline hsCRP (3) with subgroup analysis conducted across each stratum. Fourteen RCTs including 133 109 patients randomized into more intensive therapy (MIT) and less intensive therapy were selected. Meta-analysis did not demonstrate any significant differences between use of MIT and hsCRP levels (mean difference, −0.02; CI, −0.06, 0.02; P = 0.31). The MIT significantly reduced the risk of MACE (RR, 0.82; CI, 0.75, 0.91; P < 0.001). The relative risk and absolute risk remained consistent across the strata. However, there was a 0.5% statistically significant absolute risk reduction in all-cause mortality in patients with higher hsCRP (RD, −0.005; CI, −0.009, −0.001; P = 0.01). Overall, LDL-c lowering therapies reduce relative risk of MACEs particularly in patients with higher baseline hsCRP. However, there appears to be a residual inflammatory risk despite the use of contemporary lipid lowering agents.
- 14 October 2019
- Published by Oxford University Press (OUP) in European Heart Journal - Quality of Care and Clinical Outcomes
- Vol. 6 (2) , 105-111
Residual inflammatory risk after contemporary lipid lowering therapy
Recently, there has been an increasing interest in targeting inflammation to reduce major adverse cardiovascular events (MACE) in patients with cardiovascular risk. Statins, PCSK9 inhibitors, and ezetimibe have been shown to reduce MACE owing to reduction in low-density lipoproteins cholesterol (LDL-c). Herein, we investigate whether the intensity of these agents is associated with (i) discernible reduction in inflammation measured by the levels of high-sensitivity C-reactive protein (hsCRP); (ii) reduction in MACE; (iii) if there is an association between the baseline hsCRP and MACE. Electronic databases were searched for randomized controlled trials (RCTs) that compared statins, ezetimibe, PCSK9 inhibitors with placebos/active controls and reported MACEs and hsCRP (mg/L). Studies were stratified based on baseline hsCRP (3) with subgroup analysis conducted across each stratum. Fourteen RCTs including 133 109 patients randomized into more intensive therapy (MIT) and less intensive therapy were selected. Meta-analysis did not demonstrate any significant differences between use of MIT and hsCRP levels (mean difference, −0.02; CI, −0.06, 0.02; P = 0.31). The MIT significantly reduced the risk of MACE (RR, 0.82; CI, 0.75, 0.91; P < 0.001). The relative risk and absolute risk remained consistent across the strata. However, there was a 0.5% statistically significant absolute risk reduction in all-cause mortality in patients with higher hsCRP (RD, −0.005; CI, −0.009, −0.001; P = 0.01). Overall, LDL-c lowering therapies reduce relative risk of MACEs particularly in patients with higher baseline hsCRP. However, there appears to be a residual inflammatory risk despite the use of contemporary lipid lowering agents.
- 1 April 2019
- Published by Elsevier in The American Journal of Medicine
- Vol. 132 (4) , 407
The Rise of Documentation and the Destruction ofModern Medicine
- 1 April 2019
- Published by Elsevier in The American Journal of Medicine
- Vol. 132 (4) , 407
The Rise of Documentation and the Destruction ofModern Medicine
- Open Access
- 6 December 2018
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
- Vol. 26 (5) , 533-543
Effects of high-density lipoprotein targeting treatments on cardiovascular outcomes: A systematic review and meta-analysis
Background: The effects of increasing high-density lipoprotein cholesterol on cardiovascular outcomes remain uncertain. Design: We conducted a meta-analysis to investigate the effects of high-density lipoprotein cholesterol modifiers (niacin, fibrates and cholesteryl ester transfer protein inhibitors) on cardiovascular outcomes. Methods: Thirty-one randomized controlled trials (154,601 patients) with a follow-up of 6 months or more and a sample size of 100 or more patients were selected using MEDLINE, EMBASE and CENTRAL database (inception January 2018). Results: High-density lipoprotein cholesterol modifiers had no statistically significant effect on cardiovascular mortality in terms of relative risk (RR) (RR 0.94, 95% confidence interval (CI) 0.89–1.00, P = 0.05, I2 = 13%) or absolute risk (risk difference −0.0001, 95% CI −0.0014, 0.0011, P = 0.84, I2 = 28%). High-density lipoprotein cholesterol modifiers reduced the RR of myocardial infarction (RR 0.87, 95% CI 0.82–0.93, P < 0.001, I2 = 37%). This significant effect was derived by the use of fibrates (RR 0.80, 95% CI 0.73–0.87, P < 0.001, I2 = 22%) and meta-regression analysis showed that this benefit was consistent with an absolute reduction in low-density lipoprotein cholesterol. High-density lipoprotein cholesterol modifiers had no effect on stroke (RR 1.00, 95% CI 0.93–1.09, P = 0.94, I2 = 25%) or all-cause mortality (RR 1.02, 95% CI 0.97–1.08, P = 0.48, I2 = 49%). Meta-regression analyses failed to demonstrate a significant association of pharmacologically increased high-density lipoprotein cholesterol with key endpoints. In studies with background statin therapy, high-density lipoprotein cholesterol modifiers had no statistically significant impact on cardiovascular mortality, myocardial infarction, stroke or all-cause mortality ( P > 0.05). Conclusion: The use of high-density lipoprotein cholesterol modifying treatments had no significant effect on cardiovascular mortality, stroke or all-cause mortality. The beneficial effect on myocardial infarction was lost when drugs were used with statin therapy.
- 6 December 2018
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
- Vol. 26 (5) , 533-543
Open AccessEffects of high-density lipoprotein targeting treatments on cardiovascular outcomes: A systematic review and meta-analysis
Background: The effects of increasing high-density lipoprotein cholesterol on cardiovascular outcomes remain uncertain. Design: We conducted a meta-analysis to investigate the effects of high-density lipoprotein cholesterol modifiers (niacin, fibrates and cholesteryl ester transfer protein inhibitors) on cardiovascular outcomes. Methods: Thirty-one randomized controlled trials (154,601 patients) with a follow-up of 6 months or more and a sample size of 100 or more patients were selected using MEDLINE, EMBASE and CENTRAL database (inception January 2018). Results: High-density lipoprotein cholesterol modifiers had no statistically significant effect on cardiovascular mortality in terms of relative risk (RR) (RR 0.94, 95% confidence interval (CI) 0.89–1.00, P = 0.05, I2 = 13%) or absolute risk (risk difference −0.0001, 95% CI −0.0014, 0.0011, P = 0.84, I2 = 28%). High-density lipoprotein cholesterol modifiers reduced the RR of myocardial infarction (RR 0.87, 95% CI 0.82–0.93, P < 0.001, I2 = 37%). This significant effect was derived by the use of fibrates (RR 0.80, 95% CI 0.73–0.87, P < 0.001, I2 = 22%) and meta-regression analysis showed that this benefit was consistent with an absolute reduction in low-density lipoprotein cholesterol. High-density lipoprotein cholesterol modifiers had no effect on stroke (RR 1.00, 95% CI 0.93–1.09, P = 0.94, I2 = 25%) or all-cause mortality (RR 1.02, 95% CI 0.97–1.08, P = 0.48, I2 = 49%). Meta-regression analyses failed to demonstrate a significant association of pharmacologically increased high-density lipoprotein cholesterol with key endpoints. In studies with background statin therapy, high-density lipoprotein cholesterol modifiers had no statistically significant impact on cardiovascular mortality, myocardial infarction, stroke or all-cause mortality ( P > 0.05). Conclusion: The use of high-density lipoprotein cholesterol modifying treatments had no significant effect on cardiovascular mortality, stroke or all-cause mortality. The beneficial effect on myocardial infarction was lost when drugs were used with statin therapy.
- Top Cited PapersOpen Access
- 2 November 2018
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 1 (7) , e183788
Association Between Obesity and Cardiovascular Outcomes
Coronary artery disease (CAD) and its ensuing complications, including myocardial infarction and heart failure, continue to be the leading cause of morbidity and mortality in the developed world and increasingly so in the developing world.1-3 Dyslipidemia has consistently been shown to be associated with atherosclerosis. The mechanistic link between dyslipidemia and atherogenesis is supported by a large number of studies demonstrating a correlation between levels of low-density lipoprotein cholesterol and major adverse cardiovascular events.4,5 Further support is provided by studies with pharmacological agents, including statins, ezetimibe, and proprotein convertase subtilisin/kexin type 9 inhibitors, which reduce low-density lipoprotein cholesterol and improve cardiovascular disease (CVD) outcomes when used for either primary or secondary prevention.6,7
- 2 November 2018
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 1 (7) , e183788
Top Cited PapersOpen AccessAssociation Between Obesity and Cardiovascular Outcomes
Coronary artery disease (CAD) and its ensuing complications, including myocardial infarction and heart failure, continue to be the leading cause of morbidity and mortality in the developed world and increasingly so in the developing world.1-3 Dyslipidemia has consistently been shown to be associated with atherosclerosis. The mechanistic link between dyslipidemia and atherogenesis is supported by a large number of studies demonstrating a correlation between levels of low-density lipoprotein cholesterol and major adverse cardiovascular events.4,5 Further support is provided by studies with pharmacological agents, including statins, ezetimibe, and proprotein convertase subtilisin/kexin type 9 inhibitors, which reduce low-density lipoprotein cholesterol and improve cardiovascular disease (CVD) outcomes when used for either primary or secondary prevention.6,7
- 1 November 2018
- Published by Elsevier in The American Journal of Medicine
- Vol. 131 (11) , e439-E439
VEST and Interpretation of a Randomized Controlled Trial
- 1 November 2018
- Published by Elsevier in The American Journal of Medicine
- Vol. 131 (11) , e439-E439
VEST and Interpretation of a Randomized Controlled Trial
- 1 September 2017
- Published by Elsevier in The American Journal of Cardiology
- Vol. 120 (5) , 774-781
Meta-analysis of Placebo-Controlled Randomized Controlled Trials on the Prevalence of Statin Intolerance
- 1 September 2017
- Published by Elsevier in The American Journal of Cardiology
- Vol. 120 (5) , 774-781
Meta-analysis of Placebo-Controlled Randomized Controlled Trials on the Prevalence of Statin Intolerance
- 1 May 2016
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Quality and Outcomes
- Vol. 9 (3) , 294-302
Safety and Use of Anticoagulation After Aortic Valve Replacement With Bioprostheses
Background—: The American College of Cardiology guidelines recommend 3 months of anticoagulation after replacement of the aortic valve with a bioprosthesis. However, there remains great variability in the current clinical practice and conflicting results from clinical studies. To assist clinical decision making, we pooled the existing evidence to assess whether anticoagulation in the setting of a new bioprosthesis was associated with improved outcomes or greater risk of bleeding. Methods and Results—: We searched the PubMed database from the inception of these databases until April 2015 to identify original studies (observational studies or clinical trials) that assessed anticoagulation with warfarin in comparison with either aspirin or no antiplatelet or anticoagulant therapy. We included the studies if their outcomes included thromboembolism or stroke/transient ischemic attacks and bleeding events. Quality assessment was performed in accordance with the Newland Ottawa Scale, and random effects analysis was used to pool the data from the available studies. I 2 testing was done to assess the heterogeneity of the included studies. After screening through 170 articles, a total of 13 studies (cases=6431; controls=18210) were included in the final analyses. The use of warfarin was associated with a significantly increased risk of overall bleeding (odds ratio, 1.96; 95% confidence interval, 1.25–3.08; P P 3 months (odds ratio, 1.12; 95% confidence interval, 0.80–1.58; P =0.79). Conclusions—: Contrary to the current guidelines, a meta-analysis of previous studies suggests that anticoagulation in the setting of an aortic bioprosthesis significantly increases bleeding risk without a favorable effect on thromboembolic events. Larger, randomized controlled studies should be performed to further guide this clinical practice.
- 1 May 2016
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Quality and Outcomes
- Vol. 9 (3) , 294-302
Safety and Use of Anticoagulation After Aortic Valve Replacement With Bioprostheses
Background—: The American College of Cardiology guidelines recommend 3 months of anticoagulation after replacement of the aortic valve with a bioprosthesis. However, there remains great variability in the current clinical practice and conflicting results from clinical studies. To assist clinical decision making, we pooled the existing evidence to assess whether anticoagulation in the setting of a new bioprosthesis was associated with improved outcomes or greater risk of bleeding. Methods and Results—: We searched the PubMed database from the inception of these databases until April 2015 to identify original studies (observational studies or clinical trials) that assessed anticoagulation with warfarin in comparison with either aspirin or no antiplatelet or anticoagulant therapy. We included the studies if their outcomes included thromboembolism or stroke/transient ischemic attacks and bleeding events. Quality assessment was performed in accordance with the Newland Ottawa Scale, and random effects analysis was used to pool the data from the available studies. I 2 testing was done to assess the heterogeneity of the included studies. After screening through 170 articles, a total of 13 studies (cases=6431; controls=18210) were included in the final analyses. The use of warfarin was associated with a significantly increased risk of overall bleeding (odds ratio, 1.96; 95% confidence interval, 1.25–3.08; P P 3 months (odds ratio, 1.12; 95% confidence interval, 0.80–1.58; P =0.79). Conclusions—: Contrary to the current guidelines, a meta-analysis of previous studies suggests that anticoagulation in the setting of an aortic bioprosthesis significantly increases bleeding risk without a favorable effect on thromboembolic events. Larger, randomized controlled studies should be performed to further guide this clinical practice.